34 results about "Streptococcus suis" patented technology

The invention discloses application of epimedin A in preparation of a streptococcus suis type 2 capsule inhibitor, and belongs to the technical field of biological medicine. The compound can effectively inhibit the synthesis function of the streptococcus suis type 2 capsule, further enhances the removal effect of a host on the streptococcus suis type 2, reduces the pathogenicity of bacteria, and provides a new candidate compound and idea for preparing a capsule inhibitor of the streptococcus suis type 2 and researching and developing a novel medicine for treating streptococcus suis type 2 infection.

The invention belongs to the technical field of biology, and particularly relates to a quintuple fluorescent PCR detection reagent for porcine respiratory pathogens and application of the quintuple fluorescent PCR detection reagent. The quintuple fluorescent PCR detection reagent disclosed by the invention can achieve the purpose of simultaneously identifying and detecting actinobacillus pleuropneumoniae, haemophilus parasuis, mycoplasma hyopneumoniae, pasteurella multocida and / or streptococcus suis, and has the advantages of simplicity, convenience and rapidness in operation, high accuracy, high sensitivity and good repeatability; the method has important significance on rapid and accurate detection and epidemic disease prevention and control of clinical porcine respiratory pathogens.

This invention discloses an antimicrobial peptide cAMP-1 derived from the intestinal microorganisms of wild rodents and its applications, belonging to the field of biotechnology. The amino acid sequence of the antimicrobial peptide cAMP-1 is shown in SEQ ID NO:1. The antimicrobial peptide cAMP-1 exhibits highly efficient, rapid, and safe antimicrobial activity against Streptococcus suis type II. It significantly inhibits bacterial growth even at low concentrations, with a minimum inhibitory concentration (MIC) of 16 µg / mL. Time-kinetic kinetics results show that the antimicrobial peptide can kill all Streptococcus suis type II within 30 min and 15 min at concentrations of 2×MIC and 4×MIC, respectively. Furthermore, within several times the effective concentration range, the peptide exhibits almost no hemolytic activity and low cytotoxicity within a safe dosage range, demonstrating its promising application as a novel anti-infective candidate drug.

The application relates to a protective antigen of streptococcus suis disease and application thereof, and belongs to the technical field of biological vaccines. The amino acid sequence shown in SEQ ID No. 1 provided in the application is used as a protective antigen of streptococcus suis disease. The protective antigen is obtained by codon optimization of the nucleotide sequence shown in SEQ ID No. 2, construction of an expression vector and prokaryotic expression, and the protective antigen is verified to be capable of providing good immune cross-protection for type 2 and type 7 streptococcus suis infection in different ways. The application scheme has important significance for research on a general vaccine candidate antigen of multiple serotypes of streptococcus suis and scientific prevention and control of the disease.

The invention belongs to the technical field of biology, and discloses a polypeptide with broad-spectrum antibacterial activity and a preparation method and application thereof. The antibacterial peptide or the salt thereof is disclosed for the first time, the antibacterial peptide has a good antibacterial effect on common pathogenic bacteria (such as staphylococcus aureus, escherichia coli, salmonella enteritidis and streptococcus suis) and oral pathogenic bacteria (such as fusobacterium nucleatum and porphyromonas gingivalis), and the antibacterial peptide shows slight cytotoxicity on mammalian cells only under high concentration; and the safety is relatively high.

The invention relates to the technical field of veterinary vaccines, in particular to streptococcus suis capsular polysaccharide as well as a preparation method and application thereof. The preparation method of the streptococcus suis capsular polysaccharide is high in specificity, convenient to operate, good in repeatability, high in yield and low in cost, the extraction cost of the streptococcus suis capsular polysaccharide is further reduced, and meanwhile the polysaccharide yield is effectively increased. When the streptococcus suis capsular polysaccharide prepared by the method is further used for preparing a streptococcus suis capsular polysaccharide vaccine, the prepared streptococcus suis capsular polysaccharide vaccine shows more slight clinical symptoms than a streptococcus suis whole-cell inactivated vaccine, and has better biological safety and an excellent challenge protection effect.

The invention relates to a multiplex fluorescent quantitative PCR (polymerase chain reaction) detection method for streptococcus equi subsp. Zooepidemicus virulent strains causing swine streptococcosis, and belongs to the technical field of bacterial detection. The invention provides a primer probe group which can be used for simultaneously detecting M protein variable region genes (szm-variant) of streptococcus equi subsp.zooepidemicus, conserved genes (comB) in subsp.zooepidemicus and central nervous system infection related virulence genes (bifA) of streptococcus equi subsp.zooepidemicus through Taqman probe triple fluorescent quantitative PCR (Polymerase Chain Reaction), and is shown as SEQ ID NO.1-9 in a sequence table. The multiplex fluorescent quantitative PCR detection method for the streptococcus equi subsp. Zooepidemicus virulent strain causing the swine streptococcosis can complete nucleic acid amplification and result judgment within 1 hour. According to the detection method, the amplification result is judged through the threshold cycle number (Ct value), electrophoresis detection is not needed, and the problems of pollution, false positive and the like of an amplification product can be avoided. The detection method provided by the invention has the characteristics of simplicity, convenience and rapidness in operation, high specificity, high sensitivity and good stability.

The invention discloses a chicken intestinal bacteriophage source antibacterial peptide, and belongs to the technical field of biology. The antibacterial peptide (CGV-AMP-1) disclosed by the invention shows excellent effects of high efficiency, rapidness and safety on staphylococcus capitis and streptococcus suis type II; the antibacterial peptide (CGV-AMP-1) can inhibit the growth of bacteria at extremely low concentration (MIC 8 g / ml), and has strong bactericidal ability (MBC 32 g / ml); the time sterilization dynamics experiment proves that the bacteria can be completely killed within 120 minutes; meanwhile, the peptide is extremely high in safety, almost has no hemolytic activity in a range of several times of effective concentration, is extremely low in cytotoxicity, and shows huge potential as a novel anti-infection drug.

The present application relates to the animal medical technology field, especially to the Streptococcus suis strain and the vaccine thereof for prevention and treatment, and provides Streptococcus suis type 2, type 3 and type 9 strains screened and obtained, and a trivalent inactivated vaccine prepared by mixing the three strains, which can safely and effectively prevent and protect against the attack of the three pathogenic bacteria of Streptococcus suis.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide with activity of inhibiting human pathogenic bacteria as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common genital tract bacteria (such as staphylococcus aureus, gardnerella and candida albicans), oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The invention belongs to the technical field of microbiological detection, and particularly relates to a primer and a method for detecting a streptococcus suis drug-resistant gene and application of the primer, nucleotide sequences of the primer are shown as SEQ ID NO.1-SEQ ID NO.2. The detection primer has specificity, and accuracy and reliability of the detection primer can be ensured.

The invention pertains to a stable vaccine formulation comprising a protein denoted as IdeSsuis and the vaccine formulation comprising reduced cysteine. The invention also pertains to a vaccine formulation comprising a protein denoted as IdeSsuis and the vaccine formulation comprising reduced cysteine for use in a method for protecting pigs against a pathogenic infection of S. suis bacteria. The invention also pertains to methods of preparing the vaccine formulation, preferably wherein the method comprises a step of lyophilizing the vaccine formulation.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide for regulating and controlling micro-ecology as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni), genital tract pathogenic bacteria (such as staphylococcus aureus, gardnebacterium and enterococcus faecalis) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.

The application provides a kit for detecting penicillin and amoxicillin resistance of streptococcus suis and application thereof, and belongs to the technical field of molecular biology detection. The kit comprises a primer pair and AlwNI restriction endonuclease; the primer pair comprises primers PBP1a-2083F and PBP1a-2083R, and the sequences are shown in SEQ ID NO:1 and SEQ ID NO:2 respectively. The kit is used for detecting penicillin and amoxicillin resistance of streptococcus suis, has the advantages of high specificity, high sensitivity, low detection cost and low technical requirement, and provides reliable technology for monitoring penicillin and amoxicillin resistance of streptococcus suis in clinic.

The present application relates to the technical field of fermentation medium, more specifically, it relates to a high-density fermentation medium for streptococcus suis and preparation and application thereof.The medium comprises beef infusion powder 1-5 parts, tryptone 1-10 parts, pancreatic casein peptone 1-10 parts, soybean peptone 1-5 parts, dipotassium hydrogen phosphate 1-5 parts, sodium chloride 1-10 parts, yeast extract 1-10 parts and glucose 1-5 parts.

The application discloses a bacteriocin expressed by bacillus subtilis WB800N and application thereof. The original sequence of the bacteriocin is a bacteriocin PA from bacillus polymyxa, the nucleotide sequence of the bacteriocin PA is shown as SEQ ID NO:1, and the amino acid sequence is shown as SEQ ID NO:2. The bacteriocin PA coding gene is modified by a tag and optimized by a codon to obtain a bacteriocin PFH, the nucleotide sequence of the bacteriocin PFH is shown as SEQ ID NO:3, and the amino acid sequence is shown as SEQ ID NO:4. The bacteriocin PFH expressed by the bacillus subtilis WB800N has a good bacteriostatic effect on gram-positive bacteria such as streptococcus suis, enterococcus faecium, staphylococcus aureus and bacillus subtilis, and has a wide application prospect in the development of a new type of replacement product for infection treatment and a feed antibacterial peptide.

The application belongs to the technical field of biological medicine, and specifically discloses a kind of hybrid peptide B5PL and its application in preparation of anti-infection drugs.The amino acid sequence of the hybrid peptide B5PL is shown as SEQ ID NO.1, and research proves that the hybrid peptide B5PL can destroy bacterial cell membranes, regulate immune homeostasis, and thus play a role in preventing and treating drug-resistant Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, Streptococcus suis and Actinobacillus pleuropneumoniae infections.In a mouse peritoneal infection MRSA model, B5PL can significantly reduce lung pathological damage caused by infection, specifically manifested as improved alveolar structure integrity, reduced inflammatory cell infiltration, and significantly improved mouse survival rate, showing good anti-infection treatment potential.The hybrid peptide B5PL provided by the application is expected to become an antibiotic replacement drug, and has good application prospect.

The invention relates to the technical field of biology, and particularly discloses streptococcus suis lyase Ply2413 and application thereof. Wherein the amino acid sequence of the lyase is as shown in SEQ ID NO: 1, or the lyase is a functional variant which has the same CHAP catalytic structural domain and SH3b binding structural domain as the lyase and retains broad-spectrum splitting activity. The lyase can be prepared from the coding gene of the lyase through a recombinant expression system. The preparation method comprises the following steps: cloning a gene for coding the lyase, constructing a recombinant expression vector, transforming host cells, carrying out induced expression, purifying to obtain target lyase, and further preparing various antibacterial products. The streptococcus suis lyase Ply2413 disclosed by the invention can be used for preventing and controlling streptococcus suis, staphylococcus aureus and streptococcus uberis infection, and has the advantages of wide lysis spectrum, multiple action targets and good environmental stability; in addition, the preparation method disclosed by the invention has the advantages of simplicity and convenience in operation, high expression efficiency, large-scale production and high technical repeatability.

The invention relates to the technical field of streptococcus suis drug resistance gene detection, and particularly discloses a streptococcus suis drug resistance gene sextuple PCR detection kit and application thereof. The core of the kit is a specific primer combination, the nucleotide sequences of the specific primer combination are as shown in SEQ ID NO: 1-12, and the specific primer combination respectively aims at six key drug-resistant genes of streptococcus suis: ermB, tet (O), patB, aac (6 '')-Ie-ah (2 ')-Ia, optrA and lsa (E). By optimizing the primer concentration and reaction conditions, an efficient and stable sextuple PCR detection system is established, and amplification and detection of the six genes can be synchronously completed in a single reaction. The method has the advantages of high specificity, high sensitivity, good repeatability, simplicity and convenience in operation and the like. A high-throughput and low-cost molecular detection tool is provided for rapid diagnosis, medication guidance and epidemiological monitoring of streptococcus suis clinical multiple drug resistance, and the application prospect is wide.

This invention belongs to the field of vaccine preparation technology, and discloses the application of Streptococcus suis type 2 membrane vesicles in the preparation of vaccines and / or immune enhancers. This invention is the first to use Streptococcus suis type 2 membrane vesicles as a vaccine for animal immunization. Animal experiments have demonstrated that the Streptococcus suis type 2 membrane vesicles of this invention can induce high levels of antibodies and have a significant effect in preventing Streptococcus suis type 2 infection. It can be developed and applied as a novel vaccine to prevent Streptococcus suis type 2 disease and avoid bacterial resistance, demonstrating good practical application value. Simultaneously, this invention also discloses a vaccine for preventing Streptococcus suis type 2 and an immune enhancer.

The invention provides lactobacillus plantarum NX87 and application thereof, the lactobacillus plantarum NX87 is lactobacillus plantarum NX87, the lactobacillus plantarum NX87 is preserved in the Guangdong Microbial Culture Collection Center on April 23, 2025, the address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No. 66203; the lactobacillus plantarum NX87 is used for preventing and treating the streptococcus suis, the escherichia coli and the balloon mycosis, and the lactobacillus plantarum NX87 is used for preventing and treating the streptococcus suis, the escherichia coli and the balloon mycosis. The strain disclosed by the invention has relatively strong inhibition capability on streptococcus suis, escherichia coli and balloon mycosis, has relatively strong tolerance to acid, has good cholate tolerance, and is beneficial to colonization at parts such as intestinal mucosa and the like.

This invention discloses a novel antimicrobial peptide CGV-AMP-4 derived from chicken intestinal bacteriophage and its applications, belonging to the field of biotechnology. The antimicrobial peptide CGV-AMP-4 of this invention exhibits broad-spectrum antimicrobial activity, with particularly significant effects against Streptococcus suis type II. Simultaneously, this peptide demonstrates extremely high safety, exhibiting almost no hemolytic activity within several times the effective concentration range and very low cytotoxicity, showcasing great potential as a novel anti-infective drug.

The present application is suitable for the technical field of genetic engineering, and provides a bacteriophage chimeric lytic enzyme for killing Streptococcus suis, a nucleotide sequence of which is shown as SEQ ID NO. 1, and an amino acid sequence of which is shown as SEQ ID NO. 2. The present application also provides a preparation method of the bacteriophage chimeric lytic enzyme, comprising the following steps: recombinant expression of bacteriophage chimeric lytic enzyme ClyU, construction of a vector; transformation of an expression vector pET-15b-ClyU; expression and purification of the bacteriophage chimeric lytic enzyme ClyU. The present application also provides an application of the bacteriophage chimeric lytic enzyme in inhibiting and killing Streptococcus suis. The present application also provides an application of the bacteriophage chimeric lytic enzyme in preparing a pharmaceutical composition for killing Streptococcus suis. The present application constructs a bacteriophage chimeric lytic enzyme for efficiently killing Streptococcus suis through gene splicing technology, and the bacteriophage chimeric lytic enzyme has strong lytic activity and a wide lytic spectrum for Streptococcus suis, and can effectively kill Streptococcus suis.

The invention belongs to the technical field of microbiological detection, and particularly relates to a primer and method for detecting streptococcus suis and application. The nucleotide sequences of the primer for detecting the streptococcus suis are shown as SEQ ID NO.1 and SEQ ID NO.2, and the target gene is recA; the nucleotide sequences of the primers for detecting the virulence gene of the streptococcus suis are shown as SEQ ID NO.3 and SEQ ID NO.4, and the virulence gene is sly. The detection gene amplification primers do not influence each other, so that the accuracy and reliability of the detection gene amplification primers can be ensured.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.

The present application belongs to the technical field of medicine and pharmacy, and in particular relates to an application of proto-prosolan in preparation of a Streptococcus suis type 2 capsule inhibitor. The present application discloses that proto-prosolan can significantly weaken the pathogenicity and immune escape ability of Streptococcus suis type 2 by inhibiting capsule synthesis, and then effectively plays an anti-infection role. Compared with vaccines, antibodies and phage enzymes and other highly limited anti-capsule strategies specific to serotypes, proto-prosolan, as an anti-toxicity inhibitor of Streptococcus suis type 2, has potential advantages such as broad spectrum, and has important scientific significance and application value for the research and development of new anti-drugs in the future. The proto-prosolan can be applied to the preparation of a Streptococcus suis type 2 capsule inhibitor and a drug for preventing and treating Streptococcus suis type 2 infection.

This invention discloses a triple inactivated vaccine against porcine circovirus type 2 (PCV2), Mycoplasma hyopneumoniae, and Streptococcus suis, and its preparation method, belonging to the field of veterinary biological products technology. The invention consists of an antigen and a vaccine adjuvant; the antigen is composed of PCV2 antigen, Mycoplasma hyopneumoniae antigen, and Streptococcus suis antigen; the PCV2 antigen is the PCV-2 d-cap protein obtained through genetic engineering; the Mycoplasma hyopneumoniae antigen is inactivated Mycoplasma hyopneumoniae (ES-2) bacterial suspension; the Streptococcus suis is inactivated SS2 and SS9 type Streptococcus suis bacterial suspension; the adjuvant is a novel aqueous adjuvant capable of enhancing cellular and humoral immunity. The triple inactivated vaccine against PCV2, Mycoplasma hyopneumoniae, and Streptococcus suis provided by this invention exhibits significant advantages in preventing these three swine diseases.

The invention provides for a vaccine against S. suis serotype 2. The vaccine comprises chemically synthesized fragments and thus may be made widely commercially available. The vaccine is used in the livestock production and may be adapted for use against other serotypes of S. suis such as serotypes 1, 1 / 2, 3, 9, and 14. Also, the vaccine may be adapted for use in humans.

This invention discloses a *Streptococcus suis* type II double-gene deletion strain and its application. The strain preservation number of the *Streptococcus suis* type II double-gene deletion strain is: CCTCC NO: M 2023119, and its name is: Streptococcus suis II ZJJX081101‑ΔSodA‑ΔTrxB.